MTOR and hepatocellular carcinoma: Recent improvements in the prevalence of HCC recurrence may be attributed to novel immunosuppressant strategies, including the use of mTOR inhibitors such as sirolimus and everolimus [28,29], and improved patient selection with stringent criteria [30].